Documents were found describing Merck compensating investigators with honoraria for agreeing to serve as au-thors on review manuscripts ghostwrit-ten on their behalf by medical publish-ing companies. Honoraria varied, ranging from $750 to $2500. One au-thor refused his honorarium from Sci-entific Therapeutics Information stat-ing, “I really do not feel it is appropriate to be paid for this type of effort.” 76 Financial Support Disclosure There were 96 relevant published articles including 24 clinical trials and 72 reviews ( TABLE ). Of the 24 clinical trials, 22 (92%) published a disclo-sure of Merck’s financial support. Of the 72 reviews (38 of which published any financial disclosures, and 34 of which either did not require or did not publish financial disclosures), 36 (50%) published either a disclosure of Merck sponsorship or a disclosure of whether the author had received any financial compensation from the company. Among 24 nonpharmacological, hu-man participant clinical articles, all 24 included at least one coauthor who was a Merck employee. Nearly all (n=22)
This is the end of the preview. Sign up
access the rest of the document.